Gastrointestinal, inflammatory, and oral microbiota protein targets

Gastrointestinal, inflammatory, and oral microbiota protein targets refers to a broad category of molecular entities involved in the oral-gut axis, a bidirectional communication pathway where oral microbes and their metabolites influence gastrointestinal health and systemic inflammation [1, 2]. These targets include host-derived proteins such as pro-inflammatory cytokines (e.g., TNF-α, IL-6, IL-1β), pattern recognition receptors (e.g., TLR2, TLR4, NOD2), and signaling molecules like NF-κB and MyD88, which are frequently overactivated in conditions like inflammatory bowel disease (IBD) [1, 3]. Additionally, the category encompasses microbial proteins and enzymes, such as nitrate reductases and short-chain fatty acid-producing enzymes, which modulate the host's immune environment and metabolic state [3, 4]. The translocation of oral pathobionts to the gut can exacerbate intestinal barrier dysfunction and trigger Th17-mediated immune responses, making these pathways prime candidates for therapeutic intervention [2, 6]. Therapeutic strategies targeting these proteins range from monoclonal antibodies that neutralize cytokines to probiotics and fecal microbiota transplantation (FMT) aimed at restoring microbial homeostasis [4, 5]. Understanding these targets is essential for developing precision medicines that address the complex interplay between the microbiome and the host immune system in chronic inflammatory and digestive disorders [2, 4].

Other names

Oral-gut axis targetsMicrobiota-associated inflammatory targetsIBD microbiota targetsGastrointestinal-oral microbial axis

Neutralization of pro-inflammatory cytokines (e.g., TNF-alpha), inhibition of Janus kinases (JAK), blockade of leukocyte trafficking via integrin antagonism, and modulation of microbial signaling pathways such as the TLR-MyD88-NF-kB axis.